I-MAB (IMAB) Inventories, Inventories Adjustments : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Inventories, Inventories Adjustments?

I-MAB's Inventories, Inventories Adjustments for the quarter that ended in Dec. 2023 was $0.00 Mil.

I-MAB Inventories, Inventories Adjustments Historical Data

The historical data trend for I-MAB's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Inventories, Inventories Adjustments Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Inventories Adjustments

Get a 7-Day Free Trial

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Inventories, Inventories Adjustments	Get a 7-Day Free Trial								-	-	-	-	-

I-MAB Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.

I-MAB (IMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Inventories, Inventories Adjustments

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.